RU2639504C2 - Химерные антигены для вакцины против вируса гепатита с - Google Patents

Химерные антигены для вакцины против вируса гепатита с Download PDF

Info

Publication number
RU2639504C2
RU2639504C2 RU2015121429A RU2015121429A RU2639504C2 RU 2639504 C2 RU2639504 C2 RU 2639504C2 RU 2015121429 A RU2015121429 A RU 2015121429A RU 2015121429 A RU2015121429 A RU 2015121429A RU 2639504 C2 RU2639504 C2 RU 2639504C2
Authority
RU
Russia
Prior art keywords
hcv
amino acids
antigen
vaccine
antigens
Prior art date
Application number
RU2015121429A
Other languages
English (en)
Russian (ru)
Other versions
RU2015121429A (ru
Inventor
КАРРЕРА Сантьяго ДУЭНЬЯС
НОРЬЕГА Дайлен АГИЛАР
КАНЬИСАРЕС Ялена АМАДОР
ПОНСЕ ДЕ ЛЕОН Лис АЛЬВАРЕС-ЛАХОНЧЕРЕ
ДОНАТО Хильян МАРТИНЕС
БЛАНКО Сонья ГОНСАЛЕС
Original Assignee
Сентро Де Инхеньерия Хенетика И Биотекнолохия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентро Де Инхеньерия Хенетика И Биотекнолохия filed Critical Сентро Де Инхеньерия Хенетика И Биотекнолохия
Publication of RU2015121429A publication Critical patent/RU2015121429A/ru
Application granted granted Critical
Publication of RU2639504C2 publication Critical patent/RU2639504C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2015121429A 2012-11-05 2013-10-28 Химерные антигены для вакцины против вируса гепатита с RU2639504C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
CU2012-0153 2012-11-05
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (2)

Publication Number Publication Date
RU2015121429A RU2015121429A (ru) 2016-12-27
RU2639504C2 true RU2639504C2 (ru) 2017-12-21

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015121429A RU2639504C2 (ru) 2012-11-05 2013-10-28 Химерные антигены для вакцины против вируса гепатита с

Country Status (15)

Country Link
US (1) US9676825B2 (forum.php)
EP (1) EP2915544B1 (forum.php)
JP (1) JP6259831B2 (forum.php)
KR (1) KR102093495B1 (forum.php)
CN (1) CN104837498B (forum.php)
AR (1) AR093341A1 (forum.php)
AU (1) AU2013339846B2 (forum.php)
CA (1) CA2901346C (forum.php)
CU (1) CU24112B1 (forum.php)
ES (1) ES2644801T3 (forum.php)
IN (1) IN2015DN03925A (forum.php)
MX (1) MX358507B (forum.php)
RU (1) RU2639504C2 (forum.php)
WO (1) WO2014067498A1 (forum.php)
ZA (1) ZA201503036B (forum.php)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017006182A1 (en) 2015-07-07 2017-01-12 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
US11324818B2 (en) 2016-09-21 2022-05-10 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
US11660332B2 (en) 2017-04-27 2023-05-30 The Trustees Of The University Of Pennsylvania Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
CA3093314A1 (en) * 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
US20110256098A1 (en) * 2008-09-19 2011-10-20 David Apelian Immunotherapy for chronic hepatitis c virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2009131203A1 (ja) * 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110256098A1 (en) * 2008-09-19 2011-10-20 David Apelian Immunotherapy for chronic hepatitis c virus infection
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARASH ARASHKIA et al. Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice, Virus Genes, 2010, No. 40, p. 44-52. *
HUI LI et al. Genetic Diversity of Near Genome-Wide Hepatitis C Virus Sequences during Chronic Infection: Evidence for Protein Structural Conservation Over Time, PLoS ONE, 2011, Vol. 6, No. 5, p. 1-1. *
HUI LI et al. Genetic Diversity of Near Genome-Wide Hepatitis C Virus Sequences during Chronic Infection: Evidence for Protein Structural Conservation Over Time, PLoS ONE, 2011, Vol. 6, No. 5, p. 1-1. А.В. ИВАНОВ и др. МОЛЕКУЛЯРНАЯ БИОЛОГИЯ ВИРУСА ГЕПАТИТА С. Успехи биологической химии, 2005, т. 45, с. 37-86, стр. 42-49. *
А.В. ИВАНОВ и др. МОЛЕКУЛЯРНАЯ БИОЛОГИЯ ВИРУСА ГЕПАТИТА С. Успехи биологической химии, 2005, т. 45, с. 37-86, стр. 42-49. *

Also Published As

Publication number Publication date
AR093341A1 (es) 2015-06-03
CU24112B1 (es) 2015-08-27
CN104837498A (zh) 2015-08-12
CU20120153A7 (es) 2014-06-27
KR102093495B1 (ko) 2020-03-26
CA2901346C (en) 2019-04-23
US9676825B2 (en) 2017-06-13
WO2014067498A1 (es) 2014-05-08
US20150307558A1 (en) 2015-10-29
JP6259831B2 (ja) 2018-01-10
MX358507B (es) 2018-08-22
AU2013339846B2 (en) 2017-08-17
AU2013339846A1 (en) 2015-05-14
CN104837498B (zh) 2018-05-18
RU2015121429A (ru) 2016-12-27
ES2644801T3 (es) 2017-11-30
EP2915544A1 (en) 2015-09-09
ZA201503036B (en) 2016-01-27
KR20150079694A (ko) 2015-07-08
EP2915544B1 (en) 2017-08-09
IN2015DN03925A (forum.php) 2015-10-02
CA2901346A1 (en) 2014-05-08
JP2015536936A (ja) 2015-12-24
MX2015005651A (es) 2015-08-20

Similar Documents

Publication Publication Date Title
Zingaretti et al. Why is it so difficult to develop a hepatitis C virus preventive vaccine?
KR100875483B1 (ko) 백신 조성물
CN119607192A (zh) 乙型肝炎免疫方案和组合物
RU2639504C2 (ru) Химерные антигены для вакцины против вируса гепатита с
Olivera et al. Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice
CN118787737A (zh) 乙型肝炎免疫方案和组合物
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
AU746258B2 (en) Genetic immunization with nonstructural proteins of hepatitis C virus
US20070032444A1 (en) Genetic immunization with nonstructural proteins of hepatitis C virus
CN115843270A (zh) 包括缺失可变结构域的e2多肽的丙型肝炎核酸疫苗
RU2353651C2 (ru) Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с
JP2008508890A6 (ja) 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用
HK1109069B (en) Vaccine composition against hepatitis c virus

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201029